We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Substances Produced by Gut Bacteria Modulate Drug Performance

By LabMedica International staff writers
Posted on 24 Oct 2011
A recent study found that the effectiveness of a cholesterol-lowering statin was related to levels of bile acids produced by bacteria growing in the digestive tract.

Investigators at Duke University (Durham, NC, USA) employed a metabolomic approach to examine how gut bacterial influenced the efficacy of simvastatin. More...


They used a targeted gas chromatography – mass spectroscopy (GC-MS) metabolomics platform to measure a panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation to determine metabolite signatures that could predict variation in statin low-density lipoprotein-cholesterol (LDL-C) lowering efficacy. Subjects in the study were participants in the national Cholesterol and Pharmacogenetics (CAP) study. For the current experiment, the investigators selected 100 people from the CAP study whose LDL-C fell dramatically as a result of taking simvastatin; 24 who had a fairly good response on the drug; and 24 who showed little benefit.

Results published in the October 13, 2011, online edition of the journal PLoS One revealed the identity of three secondary, bacterial-derived bile acids that contributed to the magnitude of statin-induced LDL-C lowering in good responders. Bile acids and statins share transporters in the liver and intestine, and increased plasma concentration of simvastatin positively correlated with higher levels of these three secondary bile acids.

These findings, along with recently published results that the gut microbiome plays an important role in cardiovascular disease, indicate that interactions between genome, gut microbiome, and environmental influences should be considered in the study and management of cardiovascular disease. “This is personalized medicine – the effects of drugs and how we respond,” said first author Dr. Rima Kaddurah-Daouk, associate professor of psychiatry at Duke University. “We found that the benefit of statins could be partly related to the type of bacteria that lives in our guts. The reason we respond differently is not only our genetic makeup, but also our gut microbiome.”

“We really need to partner with diagnostic and pharmaceutical companies to target drugs for subpopulations,” said Dr. Kaddurah-Daouk. “… no doubt that metabolites from bacteria are playing an important role in regulating our systems. We are at a very early stage of understating this relationship, but eventually we could take a quick chemical assay and get a read on where we are metabolically.”

Related Links:
Duke University





New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.